May 3, 2022
  • UnitedHealthcare will limit coverage of Biogen Inc.’s Aduhelm across all of its plans starting June 1, saying it’s “unproven and not medically necessary for the treatment of Alzheimer’s disease due to insufficient evidence of efficacy.” UnitedHealthcare will require patients to be enrolled in a clinical trial and receive prior authorization before getting the treatment covered, following a similar Medicare decision. (Article here)